Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)
Durvalumab 和 tremelimumab 联合局部部分肿瘤消融术（射频消融术或立体定向放射治疗）治疗无法切除的转移性结直肠癌肝转移患者：EORTC-1560-GITCG 多中心单臂 II 期研究 (ILOC) 的结果
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105508
Seligmann, J; Koessler, T; Mauer, M; Evrard, S; Freedman, J; Gootjes, E C; Guckenberger, M; Govaerts, A S; Giraut, A; Ricke, J; Folprecht, G; Arnold, D; Giasafaki, P; Ducreux, M; Antunes, S; Ruers, T
